Development and validation of a polygenic hazard score to predict prognosis and adjuvant chemotherapy benefit in early-stage non-small cell lung cancer

BACKGROUND: It remains controversial who would benefit from adjuvant chemotherapy (ACT) in patients with early-stage non-small cell lung cancer (NSCLC). We aim to construct a polygenic hazard score (PHS) to predict prognosis and ACT benefit among NSCLC patients. METHODS: We conducted a retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Dan-Hua, He, Yong-Qiao, Wang, Tong-Min, Xue, Wen-Qiong, Deng, Chang-Mi, Yang, Da-Wei, Zhang, Wen-Li, Wu, Zi-Yi, Cao, Lian-Jing, Dong, Si-Qi, Jia, Yi-Jing, Yuan, Lei-Lei, Luo, Lu-Ting, Wu, Yan-Xia, Tong, Xia-Ting, Zhang, Jiang-Bo, Zheng, Mei-Qi, Zhou, Ting, Zheng, Xiao-Hui, Li, Xi-Zhao, Zhang, Pei-Fen, Zhang, Shao-Dan, Hu, Ye-Zhu, Cao, Xun, Wang, Xin, Jia, Wei-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554676/
https://www.ncbi.nlm.nih.gov/pubmed/36248337
http://dx.doi.org/10.21037/tlcr-22-139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554676/
https://www.ncbi.nlm.nih.gov/pubmed/36248337
http://dx.doi.org/10.21037/tlcr-22-139

Ejemplares similares